<?xml version="1.0" encoding="UTF-8"?>
<p>Apart from a general warning, the FDA has cautioned against the indiscriminate use of CQ/HCQ, either alone or in combination with azithromycin, in COVID-19 patients due to the potential linkage to cardiac toxicities, including severe complications like rhythm disturbances.
 <sup>
  <xref rid="bibr60-2049936120947517" ref-type="bibr">60</xref>
 </sup> While the FDA continues to explore these adverse events and will communicate their findings with the public once more information becomes available, the latest COVID-19 NIH Treatment Guidelines Panel recommends ‘against using high-dose chloroquine (600 mg twice daily for 10 days) for the treatment of COVID-19 (AI), because the high dose carries a higher risk of toxicities than the lower dose’.
 <sup>
  <xref rid="bibr61-2049936120947517" ref-type="bibr">61</xref>
 </sup> Similarly, the EMA has advised the close monitoring of the COVID-19 patients receiving CQ/HCQ.
 <sup>
  <xref rid="bibr54-2049936120947517" ref-type="bibr">54</xref>
 </sup>
</p>
